AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27683073 — intervention group
Group type: COMPARATOR
Intervention: Biphasic bone substitute (BBS) - Maxresorb®
Number of subjects: 60
Study 25255846 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued belief about the diagnostic saliency of the task
Number of subjects: 0
Study 25255846 — intervention group
Group type: COMPARATOR
Intervention: Neutral directions
Number of subjects: 0
Study 23111014 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound dressing treatment (Prevena, KCI, Wiesbaden, Germany) with -125 mm Hg for 6 to 7 days
Number of subjects: 150
Study 23111014 — intervention group
Group type: COMPARATOR
Intervention: Conventional sterile wound dressing
Number of subjects: 150
Study 23111014 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound dressing treatment
Number of subjects: 150
Study 21307985 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management intervention (telehealth)
Number of subjects: 47
Study 21307985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 47
Study 19296295 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS (1 Hz, 90% motor threshold) applied to the left temporoparietal cortex for 10 days
Number of subjects: 40
Study 19296295 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only antipsychotics
Number of subjects: 40
Study 17095936 — intervention group
Group type: EXPERIMENTAL
Intervention: High-repetition, short-rest resistance training (three to five sets of 15-20 reps, 20 s rest)
Number of subjects: 16
Study 17095936 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 17095936 — intervention group
Group type: EXPERIMENTAL
Intervention: High-repetition, short-rest resistance training
Number of subjects: 16
Study 15271706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane in 100% oxygen
Number of subjects: 0
Study 15271706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane in 50% nitrous oxide/50% oxygen
Number of subjects: 0
Study 15271706 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane in 50% nitrous oxide/50% oxygen
Number of subjects: 0
Study 15271706 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 0
Study 15271706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 15271706 — intervention group
Group type: COMPARATOR
Intervention: All groups (Sevoflurane and Halothane)
Number of subjects: 0
Study 10337723 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins and antioxidants
Number of subjects: 0
Study 10337723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre supplementation
Number of subjects: 0
Study 10337723 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 0
Study 10337723 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 0
Study 10337723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary modifications
Number of subjects: 0
Study 10337723 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8943580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine treatment trial
Number of subjects: 0
Study 1742266 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% solution of povidine-iodine for pre-operative skin preparation
Number of subjects: 0
Study 1742266 — intervention group
Group type: COMPARATOR
Intervention: No skin preparation (control group)
Number of subjects: 0
Study 6128012 — intervention group
Group type: EXPERIMENTAL
Intervention: Org NC 45 (0.1 mg kg‐1)
Number of subjects: 50
Study 6128012 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (0.1 mg kg‐1)
Number of subjects: 50
Study 6128012 — intervention group
Group type: EXPERIMENTAL
Intervention: Org NC 45
Number of subjects: 50
Study 6128012 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 50
Study 30887190 — intervention group
Group type: EXPERIMENTAL
Intervention: CHTC + SUM
Number of subjects: 70
Study 30887190 — intervention group
Group type: EXPERIMENTAL
Intervention: CHTC + CT videos + SUM
Number of subjects: 70
Study 30887190 — intervention group
Group type: COMPARATOR
Intervention: CHTC
Number of subjects: 70
Study 28493510 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.45 mg.kg‐1 with neostigmine (50 μg.kg‐1 with glycopyrrolate 10 μg.kg‐1)
Number of subjects: 44
Study 28493510 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.90 mg.kg‐1 with sugammadex (4 mg.kg‐1)
Number of subjects: 44
Study 24786514 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy Resistance Exercise (HRE)
Number of subjects: 0
Study 24786514 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 0
Study 22451244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 5 mg oxycodone hydrochloride
Number of subjects: 15
Study 22451244 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution of 5 mg oxycodone hydrochloride
Number of subjects: 15
Study 22451244 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule of 5 mg oxycodone hydrochloride
Number of subjects: 15
Study 22451244 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release tablet of 5 mg oxycodone hydrochloride
Number of subjects: 15
Study 20965827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed magnetic field treatment (20-40 mT, 50 Hz, 20 min per time, 1 time per day for 14 days)
Number of subjects: 65
Study 20965827 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 65
Study 18044282 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.8-microg/kg bolus, 0.4 microg kg(‐1) h)
Number of subjects: 80
Study 18044282 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study 16247147 — intervention group
Group type: EXPERIMENTAL
Intervention: MR angiography
Number of subjects: 157
Study 16247147 — intervention group
Group type: COMPARATOR
Intervention: MDCT angiography
Number of subjects: 157
Study 12233986 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 166
Study 12233986 — intervention group
Group type: COMPARATOR
Intervention: Cocaine use
Number of subjects: 166
Study 9872822 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (Foradil) 24 microgram, twice a day for 8 weeks
Number of subjects: 64
Study 9872822 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 400 microgram, twice a day for 8 weeks
Number of subjects: 64
Study 9872822 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo inhaled twice a day for 8 weeks
Number of subjects: 64
Study 7720758 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 12.5-50 mg per day (divided in 2-3 doses) p.o. in addition to 'conventional' therapy with digoxin and diuretics
Number of subjects: 19
Study 7720758 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only (control group)
Number of subjects: 19
Study 1827043 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol, furosemide, and minoxidil combination
Number of subjects: 30
Study 7075115 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 82
Study 7075115 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin
Number of subjects: 82
Study 7075115 — intervention group
Group type: COMPARATOR
Intervention: Comparison of predicted levels
Number of subjects: 82
Study 30291547 — intervention group
Group type: EXPERIMENTAL
Intervention: Animation-assisted education program (4.29 minutes duration)
Number of subjects: 80
Study 30291547 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no animation-assisted education)
Number of subjects: 80
Study 30765298 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal bundling intervention (promoted through displays and point-of-purchase messaging for 4 weeks)
Number of subjects: 300
Study 30765298 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reminders (weekly messages based on behavioral psychology principles)
Number of subjects: 300
Study 30765298 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 300
Study 29929537 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (up to 4 mg orally)
Number of subjects: 50
Study 29929537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert)
Number of subjects: 50
Study 27090728 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic splanchnicectomy
Number of subjects: 52
Study 27090728 — intervention group
Group type: COMPARATOR
Intervention: Analgesic pharmacotherapy
Number of subjects: 52
Study 24108527 — intervention group
Group type: EXPERIMENTAL
Intervention: Galsulfase 1.0 mg/kg/week
Number of subjects: 4
Study 24108527 — intervention group
Group type: EXPERIMENTAL
Intervention: Galsulfase 2.0 mg/kg/week
Number of subjects: 4
Study 24108527 — intervention group
Group type: EXPERIMENTAL
Intervention: Galsulfase 1.0 mg/kg/week and 2.0 mg/kg/week
Number of subjects: 4
Study 22042159 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with a woman via computer
Number of subjects: 0
Study 22042159 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipation of interaction with a woman
Number of subjects: 0
Study 22042159 — intervention group
Group type: COMPARATOR
Intervention: No interaction or information about woman's attractiveness
Number of subjects: 0
Study 19556526 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training with body weight support on a treadmill (n=52)
Number of subjects: 97
Study 19556526 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with overground gait training only (n=45)
Number of subjects: 97
Study 17456677 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal (TF) epidural steroid injection
Number of subjects: 90
Study 17456677 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlaminar (IL) epidural steroid injection
Number of subjects: 90
Study 17456677 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal (C) epidural steroid injection
Number of subjects: 90
Study 17593956 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 373
Study 17593956 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A and Zinc
Number of subjects: 373
Study 17593956 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrients
Number of subjects: 373
Study 17593956 — intervention group
Group type: COMPARATOR
Intervention: Zinc or Multiple Micronutrients
Number of subjects: 373
Study 17593956 — intervention group
Group type: COMPARATOR
Intervention: Upper Respiratory Symptoms
Number of subjects: 373
Study 17593956 — intervention group
Group type: COMPARATOR
Intervention: Incidence of Pneumonia
Number of subjects: 373
Study 15237417 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing heroin
Number of subjects: 0
Study 15237417 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin provision in the Netherlands
Number of subjects: 0
Study 15237417 — intervention group
Group type: EXPERIMENTAL
Intervention: Critique on the heroin RCT
Number of subjects: 0
Study 11077586 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic placement behind the cardia (RKP)
Number of subjects: 101
Study 11077586 — intervention group
Group type: COMPARATOR
Intervention: Retrogastric placement (RGP)
Number of subjects: 101
Study 8885803 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aqueous nasal spray (220 micrograms/day)
Number of subjects: 140
Study 8885803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 1333781 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg (C200)
Number of subjects: 8
Study 1333781 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg (C400)
Number of subjects: 8
Study 1333781 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 800 mg (C800)
Number of subjects: 8
Study 1333781 — intervention group
Group type: COMPARATOR
Intervention: Celiprolol (C200, C400, C800)
Number of subjects: 8
Study 1333781 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (C400, C800)
Number of subjects: 8
Study 1333781 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (A50, A100, A200)
Number of subjects: 8
Study 1333781 — intervention group
Group type: COMPARATOR
Intervention: Nadolol (N40)
Number of subjects: 8
Study 1333781 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 6724256 — intervention group
Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid (1 g/day)
Number of subjects: 10
Study 6724256 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid (1 g/day)
Number of subjects: 10
Study 31070386 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol brief motivational intervention (BMI) plus substance-free activity session (SFAS)
Number of subjects: 393
Study 31070386 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol brief motivational intervention (BMI) plus relaxation training (RT)
Number of subjects: 393
Study 31070386 — intervention group
Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 393
Study 30125731 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stay unit (SSU) management of AHF (<24 hours)
Number of subjects: 0
Study 30125731 — intervention group
Group type: COMPARATOR
Intervention: Standard hospitalization for AHF
Number of subjects: 0
Study 27452372 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 13
Study 27452372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 24268822 — intervention group
Group type: COMPARATOR
Intervention: Conventional drilling
Number of subjects: 30
Study 24268822 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 30
Study 22121923 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(cystatin C)
Number of subjects: 857
Study 22121923 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR(creatinine)
Number of subjects: 857
Study 22121923 — intervention group
Group type: COMPARATOR
Intervention: Combined cystatin C- and creatinine-based estimation of GFR
Number of subjects: 857
Study 19723695 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan add-on treatment
Number of subjects: 3031
Study 19723695 — intervention group
Group type: COMPARATOR
Intervention: Non-ARB treatment
Number of subjects: 3031
Study 17484536 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 58
Study 17484536 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 58
Study 16080838 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glucose-insulin-potassium (GIK) infusion for 24 hours
Number of subjects: 74
Study 16080838 — intervention group
Group type: COMPARATOR
Intervention: Vehicle group (non-GIK)
Number of subjects: 74
Study 11786288 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed women
Number of subjects: 148
Study 11786288 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed women
Number of subjects: 148
Study 11786288 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 148
Study 11786288 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American women
Number of subjects: 148
Study 9667263 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive preoperative chemotherapy regimen (two courses of cisplatin and doxorubicin in addition to high‐dose methotrexate and bleomycin, cyclophosphamide, and dactinomycin)
Number of subjects: 73
Study 9667263 — intervention group
Group type: COMPARATOR
Intervention: Control arm (therapy based on the T10 protocol)
Number of subjects: 73
Study 9667263 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive preoperative chemotherapy regimen
Number of subjects: 73
Study 9667263 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 73
Study 8138256 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment for 4 months
Number of subjects: 33
Study 8138256 — intervention group
Group type: COMPARATOR
Intervention: Nontreated control group
Number of subjects: 33
Study 2686525 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 632
Study 31280705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ficolled bone marrow
Number of subjects: 19
Study 31280705 — intervention group
Group type: COMPARATOR
Intervention: BM buffy coat
Number of subjects: 19
Study 28270726 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (30 minutes daily for 2 weeks)
Number of subjects: 56
Study 28270726 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy only)
Number of subjects: 56
Study 25681965 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 days of antibiotic therapy
Number of subjects: 70
Study 25681965 — intervention group
Group type: COMPARATOR
Intervention: 14 days of antibiotic therapy
Number of subjects: 70
Study 24570387 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (anodal tDCS, 2 mA for 7 min to the primary motor cortex)
Number of subjects: 75
Study 24570387 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (tDCS electrode montage with only 30 s of active tDCS stimulation)
Number of subjects: 75
Study 24570387 — intervention group
Group type: COMPARATOR
Intervention: Natural history group (no tDCS montage, same pain stimulation)
Number of subjects: 75
Study 24570387 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 75
Study 22884794 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 32
Study 22884794 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 32
Study 20137437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal injection of diprospan (compound betamethasone) 3 ml (B group)
Number of subjects: 60
Study 20137437 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional injection of diprospan (compound betamethasone) 1 ml + songmeile (cervus & cucumis polypeptide injection) 2 ml (C group)
Number of subjects: 60
Study 20137437 — intervention group
Group type: COMPARATOR
Intervention: Intradiscal injection of normal saline 3 ml (A group, control)
Number of subjects: 60
Study 18075283 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute insulin infusion (euglycemic hyperinsulinemic clamp)
Number of subjects: 16
Study 15007248 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy in locally advanced gastric cancer
Number of subjects: 0
Study 15007248 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiochemotherapy in gastric cancer
Number of subjects: 0
Study 15007248 — intervention group
Group type: EXPERIMENTAL
Intervention: New substances like taxanes or irinotecan
Number of subjects: 0
Study 12614251 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily plus simplified bladder training (BT)
Number of subjects: 505
Study 12614251 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine alone
Number of subjects: 505
Study 10325795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose administered into the mouth
Number of subjects: 0
Study 10325795 — intervention group
Group type: COMPARATOR
Intervention: Sucrose administered intragastrically
Number of subjects: 0
Study 7569002 — intervention group
Group type: EXPERIMENTAL
Intervention: Split course therapy
Number of subjects: 273
Study 7569002 — intervention group
Group type: COMPARATOR
Intervention: Conventional daily radiation therapy
Number of subjects: 273
Study 2022800 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg daily)
Number of subjects: 15000
Study 2022800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15000
Study 7015797 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg once daily, increased to 200 mg if needed)
Number of subjects: 55
Study 7015797 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once daily, increased to 200 mg if needed)
Number of subjects: 55
Study 7015797 — intervention group
Group type: COMPARATOR
Intervention: Both metoprolol and atenolol
Number of subjects: 55
Study 30587066 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treadmill exercise
Number of subjects: 156
Study 30587066 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 156
Study 28335446 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational poster and accompanying evaluation and triage guide
Number of subjects: 1171
Study 26716547 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol combined with topical timolol maleate (Experimental group A)
Number of subjects: 31
Study 26716547 — intervention group
Group type: COMPARATOR
Intervention: Oral propranolol alone (Control group B)
Number of subjects: 31
Study 24868014 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% H(2)O(2) bleaching agent with TiO_N photocatalyzed with LED/laser light (HP15)
Number of subjects: 40
Study 24868014 — intervention group
Group type: COMPARATOR
Intervention: 35% H(2)O(2) (HP35)
Number of subjects: 40
Study 21738095 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician education alone (GI)
Number of subjects: 1322
Study 21738095 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician education in combination with motivational counseling (MC)
Number of subjects: 1322
Study 21738095 — intervention group
Group type: COMPARATOR
Intervention: Postal dissemination of the guideline (Control group, C)
Number of subjects: 1322
Study 19711034 — intervention group
Group type: EXPERIMENTAL
Intervention: General endotracheal anesthesia for transfemoral valve implantation
Number of subjects: 100
Study 19711034 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral valve implantation
Number of subjects: 100
Study 19711034 — intervention group
Group type: EXPERIMENTAL
Intervention: Transapical valve implantation
Number of subjects: 100
Study 19711034 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-valve implantation
Number of subjects: 100
Study 17241304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (400 mg b.i.d.), tetracycline (500 mg q.i.d.), and metronidazole (250 mg q.i.d.)
Number of subjects: 100
Study 17241304 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg b.i.d.), amoxicillin (1 g b.i.d.), and omeprazole (20 mg b.i.d.)
Number of subjects: 100